Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Developers request revocation of remdesivir’s ODD for COVID-19

2
SHARES

Gilead Sciences say they are confident they can maintain an expedited regulatory review timeline for remdesivir as a treatment for COVID-19 without Orphan Drug Designation (ODD).

coronavirus particles in yellow on a blue background

The producers of remdesivir, an investigational antiviral medication, have requested the US Food and Drug Administration (FDA) rescind the Orphan Drug Designation (ODD) it was granted for the treatment of COVID-19.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

According to the Gilead Sciences, who produce remdesivir, their recent interactions with regulatory agencies has demonstrated that submissions and reviews relating to the drug for the treatment of COVID-19 are being expedited. The company submitted the request as the they are confident that they can maintain an expedited regulatory review timeline without ODD. As such they are waiving all benefits associated with the designation.

ODD is granted by the FDA in situations where the disease that may be treated affects fewer than 200,000 patients in the US. Technically the ODD still applies to remdesivir as the most recent statistics indicate the number of active cases is 61,808.1

One of the benefits of ODD is that the requirement of a paediatric study plan is waived prior to the submission of a New Drug Application.

Gilead stated that they recognise the urgent public health needs posed by the COVID-19 pandemic and will continue to develop remdesivir as quickly as possible, providing updates as they become available.

Anti-malarial drugs donated to aid fight against COVID-19…

References

  1. Coronavirus: Latest figures on new COVID-19 infections and deaths [Internet]. euronews. 25 March 2020. [Cited: 25 March 2020]. Available at: https://www.euronews.com/2020/03/25/covid-19-coronavirus-breakdown-of-deaths-and-infections-worldwide
Share via
Share via